A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have been present for the past month.

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme of ESK-001 for treating plaque psoriasis.

Descartes-08, Cartesian’s lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA).

Five months after his father passed, Kenny Lewis keeps his dad's memory with him on the same baseball field his father worked on as the groundskeeper.

When healthcare providers dismiss symptoms, it can cause lasting harm. A new study reveals how such invalidation affects ...

Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and ...

Angelys Balek reveals the vision behind her brand – where sustainability, craftsmanship, and a pursuit of innovation come ...

Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this autoimmune ...